Abstract
Renal cell carcinoma (RCC) represents 2–3% of all adult malignancies. Over the last few years, many agents such as VEGF- and mTOR-inhibitor have been developed for the treatment of metastatic RCC. ...

This publication has 13 references indexed in Scilit: